Search Results - sri+krishna

7 Results Sort By:
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary: The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations. Description of Technology: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery
Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer
Summary: The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer. Description of Technology: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary: The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies. Description of Technology: Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Steven Rosenberg, Gregoire Altan-Bonnet, Sri Krishna, Paul Robbins, Frank Lowery
Keywords(s): act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes
Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
CRISPR Platform & Portfolio
While genomic research has identified many genetic targets that have the potential to modify the course of a disease, there has been little translation of that into genetic therapies. However, the discovery of clustered regularly interspaced short palindromic repeat (CRISPR) segments and the subsequent development of CRISPR systems in 2011 revolutionized...
Published: 2/26/2026   |   Updated: 6/8/2023   |   Inventor(s): Radwa Ewaisha, Shayesteh Roshdi Ferdosi, Karen Anderson, Sri Krishna, Farzaneh Moghadam, Samira Kiani, Mo Reza Ebrahimkhani
Keywords(s):  
Category(s): Bioanalytical Assays, Chemistries & Devices, Cancer Therapeutics, Genomic Assays/Reagents/Tools, Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
Novel T cell Epitopes and Biomarkers for HPV-immune Therapy
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and cervical cancer is the fourth most common cancer in women worldwide. Human papillomavirus subtype 16 (HPV16) is the primary cause of most HPV-associated HNSCCs, as well as cervical cancer, making the virus a major global health threat. While there are HPV vaccines...
Published: 2/26/2026   |   Updated: 1/4/2019   |   Inventor(s): Sri Krishna, Karen Anderson, Andrew Sikora, Marshall Posner
Keywords(s):  
Category(s): Life Science (All LS Techs), Cancer Therapeutics, Vaccines/Antimicrobials, Non-Cancer Therapeutics